Form 13G Coherus Oncology For: 29 April
- Investing.com
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Coherus BioSciences Inc (CHRS)
Assess today's live Coherus BioSciences Inc (CHRS) share price, performance and insights using our live NASDAQ: CHRS stock exchange data.
Analyse the historical data and Coherus BioSciences Inc share price performance charts on this page. Our technical summary section provides analysis on Coherus BioSciences share price buy/sell indicators using real-time data (or discuss the Coherus BioSciences (CHRS) stock price today with other investors in the Coherus BioSciences NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ CHRS share price (ISIN: US19249H1032) to enhance your trading decisions with our free investment tools and resources.
What Is the Coherus BioSciences Inc Share Price Today?
The Coherus BioSciences share price today is 1.775.
What Is the Stock Symbol for Coherus BioSciences Inc
The stock symbol (or 'ticker') for Coherus BioSciences Inc is "CHRS."
What Stock Exchange Does Coherus BioSciences Inc Trade On?
Coherus BioSciences Inc is listed and trades on the NASDAQ stock exchange.
Is Coherus BioSciences Inc a Good Stock to Buy?
Determining whether Coherus BioSciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Coherus BioSciences Inc share price performance charts on this page. Our technical summary section provides analysis on Coherus BioSciences share price buy/sell indicators using real-time data (or discuss the Coherus BioSciences (CHRS) stock price today with other investors in the Coherus BioSciences NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ CHRS share price (ISIN: US19249H1032) to enhance your trading decisions with our free investment tools and resources.
What Is the Coherus BioSciences Inc Share Price Today?
The Coherus BioSciences share price today is 1.775.
What Is the Stock Symbol for Coherus BioSciences Inc
The stock symbol (or 'ticker') for Coherus BioSciences Inc is "CHRS."
What Stock Exchange Does Coherus BioSciences Inc Trade On?
Coherus BioSciences Inc is listed and trades on the NASDAQ stock exchange.
Is Coherus BioSciences Inc a Good Stock to Buy?
Determining whether Coherus BioSciences Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.740
1.830
52 wk Range
0.710
2.616
Earnings results expected today
1/2
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.7401.830
52 wk Range
0.7102.616
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CHRS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Analysts Sentiment
Strong Buy
Price Target
6.750
Upside
+280.28%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts do not anticipate the company will be profitable this year
- Form DEF 14A Coherus Oncology For: 20 April
- Investing.com
- Form 13G Coherus Oncology For: 29 April
- Investing.com
- Form DEF 14A Coherus Oncology For: 20 April
- Investing.com
- Charming Shoppes receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral
Analyst Ratings
5 Buy
1 Hold
0 Sell
Ratings:
6 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 6.750
(+280.28% Upside)
Coherus BioSciences Inc SWOT Analysis
Oncology Pivot | Coherus BioSciences transitions from biosimilars to immuno-oncology, facing challenges and opportunities in its strategic transformation |
Casdozo's Promise | Explore the potential of casdozo, Coherus's anti-IL-27 antibody, showing encouraging results in liver cancer treatment and driving pipeline advancement |
Financial Tightrope | Delve into Coherus's complex financial landscape, balancing debt obligations and cash burn against the need to fund ongoing research and development |
Market Dynamics | Analysts set price targets ranging from $1.50 to $7.00, reflecting varied perspectives on Coherus's ability to navigate competitive pressures and pipeline potential |
Coherus BioSciences Inc Earnings Call Summary for Q3/2025
- Coherus BioSciences reported Q3 2025 revenue of $11.6M (13.17% below forecast) with EPS of -$0.33, triggering a 4.79% stock decline to $1.49
- LOQTORZI net revenue increased 92% year-over-year, while the company streamlined operations by reducing headcount and divesting its biosimilar business
- R&D expenses rose 24% to $27.3M while SG&A costs decreased 11% to $24.9M, reflecting the company's strategic shift toward innovative oncology
- Management forecasts revenue growth to $16.1M in Q4 2025 and $22.5M by Q3 2026, with plans to expand sales force by 15% and launch digital education programs
- Multiple clinical data readouts are anticipated in 2026, with executives emphasizing the company's focus on 'achieving a step change in patient survival'
Last Updated: 07/11/2025, 00:02
Read Full TranscriptEarnings
Latest Release
09/03/2026
EPS / Forecast
-0.34 / -0.34
Revenue / Forecast
12.7M / 14.16M
Compare CHRS to Peers and Sector
Metrics to compare | CHRS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCHRSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.5x | 14.3x | −0.5x | |
PEG Ratio | 0.00 | 0.17 | 0.00 | |
Price/Book | 4.5x | 2.4x | 2.6x | |
Price / LTM Sales | 6.5x | 2.3x | 3.2x | |
Upside (Analyst Target) | 266.2% | 150.9% | 48.8% | |
Fair Value Upside | Unlock | 27.9% | 6.9% | Unlock |
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It also develops CHS-114, an investigational human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME) patients with head and neck squamous cell carcinoma. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreements with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. The company was incorporated in 2010 and is based in Redwood City, California.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Coherus BioSciences (NASDAQ: CHRS) Share Price Today?
The Coherus BioSciences stock price today is 1.775 USD.
What Stock Exchange Does Coherus BioSciences (CHRS) Trade On?
Coherus BioSciences is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Coherus BioSciences?
The stock symbol (also called a 'ticker') for Coherus BioSciences is "CHRS."
What Is the Current Coherus BioSciences Market Capitalisation?
As of today, Coherus BioSciences (NASDAQ: CHRS) market cap is 273.740M USD.
What Is Coherus BioSciences's (CHRS) Earnings Per Share (TTM)?
The Coherus BioSciences EPS is currently -1.563 (Trailing Twelve Months).
When Is the Next Coherus BioSciences Earnings Date?
Coherus BioSciences's next earnings report will be released on 01/05/2026.
Is CHRS a Buy or Sell From a Technical Analyst Perspective?
Based on today's Coherus BioSciences moving averages and other technical indicators, the daily buy/sell signal for CHRS stock is Neutral.
How Many Times Has Coherus BioSciences Stock Split?
Coherus BioSciences has split 0 times. (See the CHRS stock split history page for full effective split date and price information.)
How Many Employees Does Coherus BioSciences Have?
Coherus BioSciences has 147 employees, based on their latest Companies House report.
What is the current trading status of Coherus BioSciences (NASDAQ: CHRS)?
As of 01/05/2026, Coherus BioSciences (CHRS) is trading at a share price of 1.775 USD, with a previous close of 1.775 USD. The stock has fluctuated within a day range of 1.740 USD to 1.830 USD, while its 52-week range spans from 0.710 USD to 2.616 USD.
What Is Coherus BioSciences (CHRS) Price Target According to Analysts?
The average 12-month price target for Coherus BioSciences is 6.750 USD, with a high estimate of 10 USD and a low estimate of 4 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +280.28% Upside potential.
What Is the CHRS Premarket Price?
CHRS's last pre-market stock price is 1.790 USD. The pre-market share volume is 5,490.000, and the stock has decreased by 0.015, or 0.850%.
What Is the CHRS After Hours Price?
CHRS's last after hours stock price is 1.720 USD, the stock has decreased by -0.055, or -3.100%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.